Clinical Trial Update: Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tislelizumab monotherapy to salvage chemotherapy in relapsed/refractory Classical Hodgkin lymphoma; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Salvage chemotherapy
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Classical Hodgkin Lymphoma | Phase 3 | Status: TERMINATED